US Commercial Health Plan Step-Therapy Requirements for Ranibizumab Products, 2017–2025

Date: October 12, 2026
Journal: AMCP Nexus 2026
Citation: LaMountain F, Beinfeld M, Chambers J. US Commercial Health Plan Step-Therapy Requirements for Ranibizumab Products, 2017–2025. Poster presented at: European Society for Medical Oncology. Poster presented at: AMCP Nexus. October 2026. San Diego, CA.
Download Poster

More Publications

When Negotiated Prices Become The Benchmark: Prior MFPs And The Vanishing Role Of Value

View Publication

Comparative Analysis of Oncology Therapy Approvals in the U.S. and Most Favored Nation Countries

View Publication

Value of Knowing the Risk of Developing a Neurodegenerative Disease: A Discrete Choice Experiment

View Publication
View All Publications